SAN CARLOS, Calif., June 18 /PRNewswire/ -- LS9, the Renewable Petroleum Company (TM), today announced that it has named Dr. Fernando Valle as its Senior Director of Metabolic Engineering, a key position in its effort to commercially deliver a clean, renewable petroleum substitute. LS9 will offer a broad portfolio of DesignerBiofuels (TM) products that are lab-engineered for various commercial end-uses, including custom, fit-for-purpose gasoline, diesel, and jet fuel formulations.

CAMBRIDGE, MA, June 18, 2007 – AVEO Pharmaceuticals, Inc., a biotechnology company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced that its president and chief executive officer, Tuan Ha-Ngoc, has been awarded the Ernst & Young New England Entrepreneur of the Year® in the life sciences category.

 CAMBRIDGE, Mass., Jun 19, 2007 (BUSINESS WIRE) -- Helicos BioSciences Corporation (NASDAQ: HLCS) announced today the addition of new members to its executive management team as a key step in building a commercial organization. Chip Leveille has been appointed Vice President of Sales and Marketing and Mark Solakian has been named Vice President and General Counsel.

Intelligent LED lighting pioneer joins global lighting leader

Appointment Marks VisEn's Accelerating Commercial Expansion in Fluorescence Molecular Imaging Worldwide

To Apply Fermentation Research and Strain Development Expertise

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mascoma Corporation, a leader in low-carbon cellulosic biomass-to-ethanol development and production, today named James H. Flatt, Ph.D. as Senior Vice President, Research and Development. In this position, Dr. Flatt will lead the company’s initiatives to develop environmentally beneficial and cost-effective technologies to convert cellulosic biomass into ethanol.

Industry Expert, William Cotter, Joins Helicos as Vice President of Operations  

Waltham, MA, July 10, 2007 – Epitome Biosystems announced today a second licensing and development agreement with EMD Chemicals Inc., an affiliate of Merck KGaA of Germany, using Epitome’s EpiTag™ technology. The partnership will focus on developing EpiTag™ assays for the quantitative measurement of various targets, including membrane proteins. Products will be manufactured, marketed and sold worldwide for research applications by EMD through its well-known Novagen® brand. Sample analysis will be available as a service from Epitome.

Waltham, MA, July 11, 2007 – Adnexus Therapeutics today announced the expansion of its management team with the appointment of Martin I. Freed, M.D., F.A.C.P. to the newly-created role of Chief Medical Officer. Dr. Freed is an experienced drug developer in several therapeutic areas. He played a key role in the development of Avandia® (rosiglitazone maleate), a drug to treat metabolic disease, including guiding its development from a preclinical compound to the market place, and he also has experience in oncology and inflammation drug development.

Appointment Enhances VisEn's Expansion and Leadership in Fluorescence Molecular Imaging Worldwide